UTAH MEDICAL PRODUCTS, INC. (UTMD) Return on equity 2016–2025
UTAH MEDICAL PRODUCTS, INC. (UTMD) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
9.5%FY2025 · since FY2016: 17.5% → 9.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 9.5% | -2.4 pp |
| FY2024 | 11.8% | -1.1 pp |
| FY2023 | 13.0% | -1.5 pp |
| FY2022 | 14.4% | +0.6 pp |
| FY2021 | 13.8% | +3.3 pp |
| FY2020 | 10.5% | -4.1 pp |
| FY2019 | 14.6% | -6.3 pp |
| FY2018 | 20.9% | +10.0 pp |
| FY2017 | 10.9% | -6.6 pp |
| FY2016 | 17.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More UTMD financial trends
UTMD RevenueUTMD Net incomeUTMD Net marginUTMD Gross profitUTMD Gross marginUTMD Operating incomeUTMD Operating marginUTMD Operating cash flowUTMD Free cash flowUTMD Capital expendituresUTMD Stock buybacksUTMD Dividends paidUTMD Total assetsUTMD Total liabilitiesUTMD Shareholders’ equityUTMD overview →